Company News, Patents

Sytheon Obtains Isosorbide Patent

Will enter the dermatological market for treating diseases caused by autoimmune imbalances.

According to Sytheon, there are certain novel esters of isosorbide that have been found to address defects or imbalances in keratinocyte differentiation, repair skin barrier building and defense, and improve overall stratum corneum development, structure and architecture. Specifically, Sytheon says that certain esters of isosorbide are capable of modifying, recalibrating and/or regulating the expression of genes, genetic networks and cellular pathways in mammalian skin for improving and/or repai...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters